IsoRay, Inc. (NYSE MKT: ISR)
ISR is up 11.3% at the close.
Here is what is moving the stock: IsoRay Announces World’s First Cesium-131 Seeded Mesh Treatment for Advanced Rectal Cancer They have an underwriting offering is mentioned in recent releases as well.
Here is an explanation of Cesium-131 from the ISR website: IsoRay Medical™ utilizes proprietary technologies to deliver novel brachytherapy approaches to clinicians. IsoRay’s Cesium-131 isotope has been used as primary treatment for prostate cancer in over 7,000 patients. As adjuvant radiation therapy, Cesium-131 is being employed in the management of non-small cell lung cancer, intra-cranial tumors (including meningiomas), and head & neck malignancies post-surgical resection. Additionally, Cesium-131 is currently being used as monotherapy in the management of gynecologic recurrences and ocular melanomas Customized strands, meshes, and applicators are available bearing Cesium-131 sources, and the recently reintroduced GliaSite Radiation Therapy System is available for brachytherapy of the resection bed following surgical removal of gliomas and brain metastases.